Cardiovascular Complications in End-Stage Renal Disease Patients

  • George A. Porter


As we conclude 20 years of successful treatment of end-stage renal disease (ESRD) with either intermittent hemodialysis or renal transplantation, it seems appropriate to reflect on past accomplishments while identifying future challenges. Although the life expectancy for patients with terminal renal failure has been extended by these therapeutic interventions, premature cardiovascular disease still ranks as the number one threat to the longevity of this patient population. When the rate of cardiovascular mortality for end-stage renal disease patients is compared to that of the United States population, a death rate increase of between 10 and 30 times is evident (Table 1). In this setting this problem will be discussed—from the standpoint of both what is known about the pathophysiology of cardiovascular disease in end-stage renal disease, and what therapeutic manipulations are available that might modify this particular outcome.


Cardiovascular Mortality Coronary Heart Disease Mortality Intermittent Hemodialysis Analgesic Nephropathy Chronic Dialysis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Proc Eur Dial Transpl Assoc 15:40–53, 1978.Google Scholar
  2. 2.
    Proceedings of National Heart, Lung, and Blood Institute Conference on Coronary Heart Disease Mortality, October 24–25, 1978.Google Scholar
  3. 3.
    World Health Organization Statistics Annual, 1979, pp 135–141.Google Scholar
  4. 4.
    Cooper R, Stamler J, Dyer A, Garside D: The decline in mortality from coronary heart disease, USA, 1968–1975. J Chron Dis 31:709–720, 1978.PubMedCrossRefGoogle Scholar
  5. 5.
    Haire HM, Sherrard DJ, Scardapane D, Curtis FK, Brunzell JD: Smoking, hypertension, and mortality in a maintenance dialysis population. Cardiovasc Med 3:1163–1168, 1978.Google Scholar
  6. 6.
    Kannel WB, Castelli WP, Gorden T: Cholesterol in the prediction of atherosclerotic disease. Ann Intern Med 90:85, 1979.PubMedGoogle Scholar
  7. 7.
    Bennet WM, Kloster F, Rosch J, Barry J, Porter GA: Natural history of asymptomatic coronary arteriorgraphic lesions in diabetic patients with end-stage renal disease. Am J Med 65:779–784, 1978.CrossRefGoogle Scholar
  8. 8.
    Nanra RS, Stuart-Taylor J, deLeon AH, White KH: Analgesic nephropathy: Etiology clinical syndrome and cliniopathologic correlations in Australia. Kidney Int 13:79–92, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1985

Authors and Affiliations

  • George A. Porter
    • 1
  1. 1.Department of MedicineUniversity of Oregon Health Sciences CenterPortlandUSA

Personalised recommendations